JNJ vs PLSE
JNJ: A global healthcare leader spanning pharmaceuticals, medical devices, and consumer health products, with a portfolio spanning acute care, oncology, immunology, cardiovascular, and infectious disease. PLSE: Pulse Biosciences is a medical device company developing proprietary nanosecond pulsed-field ablation technology to treat atrial fibrillation and other surgical soft tissue conditions with nonthermal cellular precision.
Side-by-side fundamentals
| Metric | JNJ | PLSE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $255.63 | $32.76 | |
| Market cap as of 2026-07-23 | $614.6B | $2.3B | |
| P/E as of 2026-07-23 | 29.22 | n/a | |
| PEG as of 2026-07-23 | 3.16 | -1.99 | PLSE lower |
| Net margin as of 2026-07-23 | +21.5% | -7376.7% | JNJ higher |
| Gross margin as of 2026-07-23 | +68.0% | -21.0% | JNJ higher |
| Operating margin as of 2026-07-23 | +25.7% | -7692.4% | JNJ higher |
| ROE as of 2026-07-23 | +26.3% | -86.7% | JNJ higher |
| ROA as of 2026-07-23 | +10.7% | -73.6% | JNJ higher |
| Debt / equity as of 2026-07-23 | 0.68 | 0.00 | PLSE lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.1% | -20.6% | JNJ higher |
| Revenue CAGR (3y) SEC XBRL | +6.2% | -20.6% | JNJ higher |
| Dividend yield as of 2026-07-23 | +2.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.23 | 1.58 | |
| 1-year return as of 2026-07-22 close | +52.2% | +116.1% | PLSE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.